ASX biotech sector’s best EOFY

Bioxyne stars with a 720% gain in the 2024-25 yearParadigm shares soar 34% after $41 million convertible note dealBiotechs turn to debt funding

The ASX biotech sector’s best EOFY performer has come from left field: the local and European focused medicinal cannabis supplier

Bioxyne (ASX:BXN).

According to the Health Check Biotech Pulse – trademark pending – Bioxyne shares soared 720% in 2024-25, leaving its largely poorly performing pot peers in the dust.

Bioxyne’s fortunes have been driven by its Breathe Life Sciences arm, which purveys cannabis products including not just flowers and oils but pastilles, vapes, pessaries and suppositories (we kid you not).

The company recently upgraded full-year revenue guidance from $25 to $28 million and promised positive cash flow and – gasp! – profitability.

reported by Stickhead today